AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02545543 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator QIV
Description: The US-licensed Comparator QIV, inactivated, split-virion, thimerosal-free, quadrivalent influenza vaccine, administered as a 0.5 mL intramuscular dose. The vaccine is presented in a prefilled needleless syringe.~The subject's age and influenza vaccination history determines the dosing regimen (a single vaccination or a 2-vaccination regimen administered 28 days apart) according to the most recent US ACIP guidelines for seasonal influenza vaccination.
Study NCT03714269 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: measurement evaluated with an isokinetic dynamometer
Description: measurement of the maximum dorsiflexion angle in degrees evaluated on an isokinetic dynamometer
Study NCT03714269 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: measurement evaluated with an 2D ultrasound
Description: * simultaneous recording of force torque, joint angle and myotendinous junction displacement in 2D ultrasound during 5 passive mobilization cycles of ankle flexion-extension at very low speed~* recording of static images in 2D ultrasound representing the proximal insertion of the gastrocnemius muscle in the internal condyle of the femur, the myotendinous junction.
Study NCT03714269 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: assessment of the level of discomfort
Description: visual analogue scale (0 = no discomfort and 10 = maximal discomfort)
Study NCT01770444 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-dose Cardiac CT protocol
Description: A cardiac CT protocol modified for reduction of radiation exposure~1. Prospective gating~2. Range: dedicated imaging (below carina to heart base)
Study NCT01770444 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional cardiac CT protocol
Description: Conventional CCTA protocol~1. Retrospective gating with tube current modulation~2. Range: dedicated imaging (below carina to heart base)
Study NCT00576979 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow transplantation
Description: Occurs approximately 48 hours after completion of cyclophosphamide
Study NCT00576979 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Occurs approximately 48 hours after completion of cyclophosphamide
Study NCT00576979 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Occurs approximately 48 hours after completion of cyclophosphamide
Study NCT02081066 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: cardiovascular risk factors
Study NCT02970682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SFX-01
Description: Stabilised Sulforaphane
Study NCT02970682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant
Study NCT02970682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Tamoxifen
Study NCT02970682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase Inhibitors
Study NCT01801345 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fatigued
Study NCT01801345 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Rested
Study NCT02303418 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: Carbetocin will be given slowly iv after delivery of the baby
Study NCT02303418 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin will be given slowly iv after delivery of the baby
Study NCT00479271 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home based, flexible, stepped care intervention
Description: Home based, flexible, stepped care intervention
Study NCT00479271 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Home based, flexible, stepped care intervention after 6 months. Families will be free to choose any health care they desire during the waiting period.
Description: Home based, flexible, stepped care intervention after 6 months. Families will be free to choose any health care they desire during the waiting period.
Study NCT00270842 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi
Description: This intervention is a 10 week Tai Chi group exercise class designed specifically for persons with Peripheral Neuropathy, having difficulty feeling their feet.
Study NCT00270842 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional Balance
Description: This intervention is a 10 week Functional Balance group exercise class designed specifically for persons with Peripheral Neuropathy, having difficulty feeling their feet.
Study NCT00270842 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Education Control group
Description: This control group participated in 10 weeks of general health education classes.
Study NCT02181270 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high intensity exercise
Description: Subjects will perform 5-10 minute warm-up (50% VO2peak). Subjects will then exercise at an exercise intensity that corresponds to 90% HRmax, for 4 minutes. This will be followed by 3 min of exercise at 55% HRmax. Four of these exercise intervals/recovery periods will be completed. The total exercise commitment will be \~45 minutes
Study NCT02181270 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: continuous moderate exercise
Description: Subjects will perform a 5-10 minute warm-up at 50% VO2peak. Thereafter, the intensity of exercise will be increased to 70% VO2peak by increasing the speed and incline of the treadmill. Subjects will exercise at this intensity for 60 minutes.
Study NCT01136187 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Access site in primary PCI
Study NCT01136187 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Access site in primary PCI
Study NCT00243607 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hydrotherapy according to Kneipp rules
Description: 2-5 applications of hydrotherapy according to Kneipp rules (self application) per day
Study NCT02518880 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Parabolic flight
Study NCT02518880 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: plasma volume measurements
Study NCT02593071 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV-F Vaccine
Study NCT02593071 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Phosphate Buffer Placebo
Study NCT00539175 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: infrared light
Description: pulsed infrared light will be applied to feet, ankles and popliteal fossae of patients with diabetic neuropathy
Study NCT00539175 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: infrared light; placebo
Description: patients will be exposed to the same machine used to provide pulsed infrared light, but the light emitting diodes will not be activated. All other aspects of the treatment will be the same. The patient and investigator will be blind to treatment assignment.
Study NCT00710762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF1120
Study NCT00710762 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00436501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 25 mg/m\^2 given intravenously (IV) over 1 hour (+/- 10 minutes) following VEGF Trap every 3 weeks starting cycle 1 (21 day cycles)
Study NCT00436501 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ziv-aflibercept
Description: Starting dose 2 mg/kg given IV Cycle 0. Phase I Group: Every 3 weeks beginning with Cycle 0 (Completed 03/14/2008); Phase II Group: Every 3 weeks starting cycle 1 (Opened 05/09/2008).
Study NCT00436501 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00436501 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT01233518 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: FFR
Description: Fractional flow reserve measured during cardiac catheterization
Study NCT01761032 — intervention group
Intervention type: DEVICE
Intervention: Tanning
Description: Participants will be placed under a tanning canopy for 4-10 minutes.
Study NCT00002952 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MART-1 antigen
Description: Melan-A peptide loaded PBMCs (sc, q3wk x 3)
Study NCT00746798 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9%Normal Saline for Injection, given one time subcutaneously
Study NCT00946166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin
Description: 40 mg daily in the evening for a maximum of 14 days
Study NCT00002952 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant MAGE-3.1 antigen
Study NCT00002952 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interleukin-12
Description: rhIL-12 (4 mcg, sc, days 1, 3 and 5 of every 3 wk cycle)
Study NCT03415776 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemodialysis
Description: Renal replacement therapy
Study NCT00954096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: transdermal nicotine patch (7mg)
Description: A 7mg transdermal nicotine patch will be applied to the subject's arm for an 8 hour period.
Study NCT01892384 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo
Study NCT01892384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: BI 409306
Study NCT04686058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol 10 MG/ML Injection
Study NCT04686058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam injection
Study NCT04686058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pethidine Hydrochloride 50 Mg/mL Solution for Injection
Study NCT04686058 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: target controlled infusion pump
Study NCT04686058 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: patient-controlled sedation pump
Study NCT03279289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: 4 mg/kg administered intravenous infusion on day 1
Study NCT03279289 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: 4 mg/kg administered intravenous infusion on day 1
Study NCT03279289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 180 mg/m2 intravenous infusion
Study NCT03279289 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: 180 mg/m2 intravenous infusion
Study NCT03279289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: folinic acid (dl racemic)
Description: 400 mg/m2 intravenous infusion
Study NCT03279289 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: folinic acid (dl racemic)
Description: 400 mg/m2 intravenous infusion
Study NCT03279289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5Fluorouracil
Description: 400 mg/m2 intravenous bolus
Study NCT03279289 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5Fluorouracil
Description: 400 mg/m2 intravenous bolus
Study NCT03279289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 2400 mg/m2 continuous intravenous infusion over 46 hours
Study NCT03279289 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: 2400 mg/m2 continuous intravenous infusion over 46 hours
Study NCT01872325 — intervention group
Intervention type: BEHAVIORAL
Intervention: Education
Description: An education program will be developed using behaviour change techniques specifically mapped to address modifiable factors identified in a previous study. These techniques will include: information about the significance of agonal breathing, modeling/demonstration of desired behavioural skills, rehearsal of desired skills, and monitoring/reinforcement and feedback.
Study NCT03865888 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporins
Description: Cyclosporins eye drops to be administered in dry eyes
Study NCT03865888 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Tacrolimus eye drops to be administered in dry eyes
Study NCT01128764 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT for depression and healthy lifestyle plus exercise
Description: CBT treatment for depressed teens will be adapted into one integrated protocol that addresses depression using CBT techniques, an exercise component, and advice regarding healthy eating.
Study NCT00576979 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: Undergo IMRT
Study NCT01128764 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT for depression
Description: Standard CBT treatment for depressed teens that addresses depression using CBT techniques only
Study NCT02864901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KSL-W
Description: Plaque reducing gum
Study NCT00576979 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: tomotherapy
Description: Undergo IMRT using helical tomotherapy
Study NCT00946166 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Simvastatin-like placebo administered daily in the evening for a maximum of 14 days
Study NCT02864901 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chewing Gum Placebo
Study NCT04213651 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention for this study
Study NCT03375853 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer Based Response Training Weight Loss Intervention
Description: Participants complete four computer based training tasks each visit, over the course of a few lab visits. Participants then perform weekly booster sessions in a more natural home or community environment over the internet using the same computer based training tasks.
Study NCT03375853 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Generic Response Training Control Intervention
Description: Participants complete four computer based training tasks each visit, over the course of a few lab visits. Participants then perform weekly booster sessions in a more natural home or community environment over the internet using the same computer based training tasks.
Study NCT06056947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVEGYN A
Description: EVEGYN A: Fixed-dose combination of 600 mg fenticonazole nitrate + 1000 mg tinidazole + 100 mg lidocaine vaginal ovule Single dose, single administration (1x1)
Study NCT06056947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVEGYN B
Description: EVEGYN B: Fixed-dose combination of 600 mg fenticonazole nitrate + 2000 mg tinidazole + 100 mg lidocaine vaginal ovule Single dose, single administration (1x1)
Study NCT06056947 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gynomax® XL Vaginal Ovule
Description: 200 mg tioconazole + 300 mg tinidazole + 100 mg lidocaine single dose / day, during three consecutive days (1x1 / 3 days)
Study NCT02224898 — intervention group
Intervention type: BEHAVIORAL
Intervention: Mobile Mindfulness Therapy
Description: Subjects will be asked to complete 30 days of mobile mindfulness therapy, for 2-30 minutes daily.
Study NCT01203657 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi
Description: Tai Chi classes, 60 minutes, 2x week
Study NCT04756414 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure based face-to-face Cognitive Behavior Group Therapy
Description: See under detailed description
Study NCT01646099 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based sun protection education
Description: Prior to summer, KTRs who agree to participate will receive a text message with their access code to the Internet intervention to access from their homes on a personal device. After online completion of baseline assessments, participants will be randomized to receive the intervention or general skin care information (control). Following the initial use, the participants may revisit the Internet intervention on a personal device or at the doctor's office on a tablet PC. Over the next 6 weeks, sun protection text reminders will be sent to intervention KTRs' cell phones and they will respond that they read the message. Control participants will receive text messages about general skin care.
Study NCT00501228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: 5 mg/kg ID Once Daily x 1 Week
Study NCT00880360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ontak
Description: Patients will be treated with Ontak at 12 µg/kg monthly as long as they meet response criteria.
Study NCT00888667 — intervention group
Intervention type: OTHER
Intervention: Pacing interventions
Description: 10 seconds recording of atrial paced rhythm at 100 ppm in sitting 10 seconds recording of atrial paced rhythm at 150 ppm in supine 10 seconds recording of atrial paced rhythm at 150 ppm in sitting
Study NCT00521781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: 100 mg/m2 IVPB Day 1, 8, 15, 22, 29,36,43,50 of each cycle for 4 nine-week cycles (Each cycle of Abraxane/hormonal therapy will consist of 8 weeks of Abraxane therapy and 1 week of rest.)
Study NCT00521781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide
Description: 7.5 mg monthly or 22.5 mg quarterly, can begin within 3 months of initiating Abraxane for 2 years
Study NCT00521781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: 50 mg p.o. daily starts week 36 of initiating Abraxane.
Study NCT02048345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suspension Fasted State
Study NCT02479503 — intervention group
Intervention type: PROCEDURE
Intervention: Antibiotic prophylaxis in adult heart transplantation
Study NCT00540020 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Study NCT02048345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suspension Fed State
Study NCT02048345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solution Fasted State
Study NCT02048345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solution Fed State
Study NCT01412853 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MR-Spectroscopy
Description: response to standard radiotherapy treatment will be estimated for each patient every 3 months up to one year from the end of the radiotherapy
Study NCT02091180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol
Description: 0.5g/kg of 20% intravenous (i.v.) mannitol infusion over 10 minutes immediately before induction of anesthesia
Study NCT02091180 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Saline infusion
Study NCT01405092 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: use of continuous renal replacement machine for renal replacement
Description: usual care with volume removal during continuous renal replacement therapy
Study NCT01405092 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: use of continuous renal replacement machine for renal replacement
Description: usual care with volume removal during continuous renal replacement therapy
Study NCT01405092 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: use of blood volume monitoring device in conjunction with machine used for continuous renal replacement to assess and determine volume removal
Description: blood volume monitoring device, Critline, Hemametric, USA, will be used in conjunction with continuous renal replacement to determine rate of volume removal
Study NCT01393977 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: rehabilitation of limb function
Description: only receive rehabilitation of limb function
Study NCT01393977 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cells Transplantation
Description: mesenchymal stem cells derived from umbilical cord are transplanted directly into subarachnoid by Lumbar puncture
Study NCT00460980 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Virtual reality laparoscopic simulator training
Description: The aim of this project is to determine whether a structured approach to teaching laparoscopic skills to beginning surgeons with a virtual reality trainer will improve skills prior to actual operative experience. We aim to show that with the virtual reality trainer, operative skills will be improved and that overall operative time will be decreased.
Study NCT02538172 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: T-Track® CMV assay
Study NCT02538172 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: T-Track® CMV assay